Yehuda Handelsman to Antibodies, Monoclonal
This is a "connection" page, showing publications Yehuda Handelsman has written about Antibodies, Monoclonal.
Connection Strength
0.923
-
Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II. Diabetes Obes Metab. 2017 07; 19(7):989-996.
Score: 0.542
-
Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial. Diabetes Care. 2025 Sep 01; 48(9):1512-1516.
Score: 0.242
-
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017 12; 5(12):941-950.
Score: 0.139